Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies by Zitron, Ian M et al.
Wayne State University
Wayne State University Associated BioMed Central Scholarship
2013
Targeting and killing of glioblastoma with activated
T cells armed with bispecific antibodies
Ian M. Zitron
Wayne State University, izitron@gmail.com
Archana Thakur
Wayne State University, thakur@karmanos.org
Oxana Norkina
Wayne State University, onorkina@karmanos.org
Geoffrey R. Barger
Wayne State University, gbarger@med.wayne.edu
Lawrence G. Lum
Wayne State University, luml@karmanos.org
See next page for additional authors
This Article is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University
Associated BioMed Central Scholarship by an authorized administrator of DigitalCommons@WayneState.
Recommended Citation
Zitron et al.: Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies. BMC Cancer 2013 13:83.
Available at: http://digitalcommons.wayne.edu/biomedcentral/5
Authors
Ian M. Zitron, Archana Thakur, Oxana Norkina, Geoffrey R. Barger, Lawrence G. Lum, and Sandeep Mittal
This article is available at DigitalCommons@WayneState: http://digitalcommons.wayne.edu/biomedcentral/5
RESEARCH ARTICLE Open Access
Targeting and killing of glioblastoma with
activated T cells armed with bispecific antibodies
Ian M Zitron1†, Archana Thakur2†, Oxana Norkina2, Geoffrey R Barger3, Lawrence G Lum2,4,5 and Sandeep Mittal1*
Abstract
Background: Since most glioblastomas express both wild-type EGFR and EGFRvIII as well as HER2/neu, they are
excellent targets for activated T cells (ATC) armed with bispecific antibodies (BiAbs) that target EGFR and HER2.
Methods: ATC were generated from PBMC activated for 14 days with anti-CD3 monoclonal antibody in the
presence of interleukin-2 and armed with chemically heteroconjugated anti-CD3×anti-HER2/neu (HER2Bi) and/or
anti-CD3×anti-EGFR (EGFRBi). HER2Bi- and/or EGFRBi-armed ATC were examined for in vitro cytotoxicity using MTT
and 51Cr-release assays against malignant glioma lines (U87MG, U118MG, and U251MG) and primary glioblastoma lines.
Results: EGFRBi-armed ATC killed up to 85% of U87, U118, and U251 targets at effector:target ratios (E:T) ranging from
1:1 to 25:1. Engagement of tumor by EGFRBi-armed ATC induced Th1 and Th2 cytokine secretion by armed ATC.
HER2Bi-armed ATC exhibited comparable cytotoxicity against U118 and U251, but did not kill HER2-negative U87 cells.
HER2Bi- or EGFRBi-armed ATC exhibited 50—80% cytotoxicity against four primary glioblastoma lines as well as a
temozolomide (TMZ)-resistant variant of U251. Both CD133– and CD133+ subpopulations were killed by armed ATC.
Targeting both HER2Bi and EGFRBi simultaneously showed enhanced efficacy than arming with a single BiAb. Armed
ATC maintained effectiveness after irradiation and in the presence of TMZ at a therapeutic concentration and were
capable of killing multiple targets.
Conclusion: High-grade gliomas are suitable for specific targeting by armed ATC. These data, together with additional
animal studies, may provide the preclinical support for the use of armed ATC as a valuable addition to current
treatment regimens.
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Background
Malignant gliomas, the most lethal brain tumor in adults,
account for approximately 13,000 deaths annually in the US
[1]. Long-term prognosis for glioblastoma patients remains
poor despite surgery and chemoradiotherapy. Major rea-
sons for treatment failure include its highly infiltrative
nature and chemoresistance. Given the limitations of ag-
gressive multimodality treatment, targeted cell therapy is an
attractive therapeutic alternative.
Despite the paucity of studies, development of cell
therapy for glioblastomas has been encouraging. Arming
anti-CD3 activated T cells (ATC) with bispecific anti-
bodies (BiAb) that target the T cell receptor on one hand
and the tumor-associated antigen on the other can redi-
rect the non-MHC restricted cytotoxicity of ATC to lyse
tumors. Arming ex vivo expanded T cells with BiAbs
may not only improve clinical responses but also
minimize toxicity by avoiding the cytokine storm that
can occur by systemic infusion of BiAb alone [2].
Arming ATC with HER2Bi or EGFRBi converts every
ATC into a specific cytotoxic T cell [3-7]. Our preclinical
studies show that armed ATC can target breast [6], pros-
tate [8], ovarian [5] EGFR+ cancers (head & neck, colo-
rectal, pancreatic, lung [4], neuroblastomas [9], and
CD20+ NHL [7]. ATC armed with HER2Bi were not only
able to lyse cancer cells that have high (3+) expression
of HER2 but more importantly target and lyse MCF-7
cells that express low or nil HER2 expression [6] More-
over, armed ATC can kill multiple times, secrete
cytokines/chemokines and multiply after engaging tumor
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cells in vitro [10]. In vivo anti-tumor activity of armed
ATC when co-injected with tumor cells to prevent the
tumor development or when injected intratumorally into
xenograft model of prostate cancer, armed ATC persist
in Beige/SCID mice for 91 days in the spleen and bone
marrow without interleukin-2 (IL-2) support [8,11]. Intra-
venous infusions of armed ATC inhibit tumor growth in
the xenograft models in colon [4] and ovarian cancer [5].
In our phase I clinical trial involving stage IV breast cancer
patients who received activated T cells (ATC) armed with
anti-CD3×anti-Her2/neu bispecific antibody (HER2Bi),
high levels of circulating tumoricidal cytokines and specific
cytotoxicity by PBMC were observed [10]. In an earlier trial,
using targeted therapy, lymphokine activated killer (LAK)
cells armed with chemically heteroconjugated bispecific
antibody (anti-CD3MAb x anti-glioma MAb) in 10 patients
showed promising clinical results. In 10 patients, 4 patients
had regression of tumor and another 4 patients showed
histological eradication of remaining tumor cells post sur-
gery with no recurrence in 10–18 months follow-up [12].
ATC armed with HER2Bi and/or anti-CD3×anti-EGFR
(EGFRBi) produced by chemical heteroconjugation of anti-
CD3 (OKT3) with trastuzumab or cetuximab, respectively,
offers a compelling choice for adjuvant immunotherapy
following surgery and chemoradiotherapy.
Although immortalized glioma lines can provide useful
biologic insights, cell lines from freshly-resected tumors
may more accurately represent the behavior of glioma
cells in vivo. In this study, we first established that pri-
mary glioma cells can be killed by armed ATC and then
addressed further questions of therapeutic relevance: 1)
Does dual targeting with BiAbs by mixing individual
populations of EGFRBi- and HER2Bi-armed ATC or
arming ATC with both BiAbs simultaneously enhance
specific cytotoxicity? 2) Can CD133 enriched, CD133−
and unfractionated tumor cells be killed differentially by
armed ATC? 3) Will armed ATC eliminate a temozolomide
(TMZ) resistant subline of U251MG? 4) Do armed ATC
continue to kill after being irradiated and in the presence
of TMZ? 5) Does binding of armed ATC to glioma cell
lines induce the secretion of cytokines?
Methods
Generation and expansion of activated T cells
Anti-CD3-activated ATC were expanded in culture from
human peripheral blood mononuclear cells (PBMC) [6].
Briefly, ATC were produced by activating PBMC with
20 ng/ml of soluble anti-CD3 (OKT3, Ortho Pharmaceut-
ical, Raritan, NJ) and expanded in IL-2 (aldesleukin, Pro-
metheus Laboratories Inc., San Diego, CA) (100 IU/ml) in
RPMI 1640 medium supplemented with 10% fetal calf
serum (FCS), 2 mM L-glutamine, and 1% penicillin-
streptomycin for 14 days. After culture, ATC were
harvested, washed, counted, and resuspended in RPMI
1640 for immediate use or cryopreserved.
In experiments where ATC were irradiated, cells received
a single 2500 cGy dose using a blood bank cell irradiator
(Nordion, Ottawa, Canada) to prevent lymphocyte pro-
liferation [10] and determine whether cytotoxic activity of
BiAb-armed ATC is radioresistant.
Bispecific antibodies and arming of ATC
Preparation and characteristics of BiAbs have been
described previously [3,6]. HER2Bi was prepared by
chemical heteroconjugation of OKT3 and trastuzumab
(HerceptinW, Genentech, South San Francisco, CA).
EGFRBi was produced by chemical heteroconjugation of
OKT3 and cetuximab (ErbituxW, Bristol-Myer Squibb, NY).
Anti-CD3×anti-CD20 BiAb (CD20Bi) was made from
heteroconjugation of OKT3 and rituximab (RituxanW,
Genentech, South San Francisco, CA) [7]. ATC were armed
with BiAbs at 50 ng/106 cells for 1 hour at 4°C, washed,
and resuspended in complete RPMI 1640.
Ex vivo primary glioblastoma lines
Tumor tissue was washed with PBS+EDTA (2 mM),
chopped into fragments ≤1 mm, and enzymatically
digested using Accumax (Innovative Cell Technologies,
San Diego, CA). Fragments of undigested tissue were
removed by low g sedimentation and cell clumps were
removed by tissue sieves. Contaminating erythrocytes
were removed by centrifugation over Ficoll-Hypaque.
Viable single cells were counted using trypan blue exclu-
sion. Culture of the ex vivo adherent differentiated glioma
cells was carried out in DMEM-F12 medium (Mediatech,
Manassas, VA) supplemented with 10% FCS (Atlanta
Biologicals, Atlanta, GA), L-glutamine, and gentamicin
(10 μg/ml). Propagation of neurospheres containing cells
with stem-like properties was performed in Neurobasal
medium (Invitrogen, Carlsbad, CA) containing N-2 and
B-27 supplements, human recombinant EGF, and human
recombinant basic FGF (each at 20 ng/ml) (PeproTech,
Rocky Hill, NJ) [13].
Long-term glioblastoma lines
Glioma cell lines U87MG, U118MG, and U251MG were
also cultured as adherent monolayers in the DMEM-
F12-based medium. U87 and U251 cells were grown in
6-well plates in medium supplemented with TMZ over a
range of concentrations (10—1000 μM). Medium was
changed every 3 days, maintaining the original TMZ
concentration. Over 2 weeks, growth of U87MG cells
was unaffected, whereas loss of some U251MG cells was
recognizable at 10 μM and progressively increased such
that a few surviving cells were identified at 333 μM
TMZ, but none at 1000 μM. The cells selected in
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333 μM TMZ were subsequently propagated in medium
containing TMZ (333 μM).
Antibodies, cell separation, and cellular phenotyping
Monoclonal antibodies (cetuximab, trastuzumab, and
rituximab) were labeled with the N-hydroxysuccinimide
ester of Alexa Fluor 488 (Invitrogen, Carlsbad, CA). These
reagents were used for flow cytometry at 1—10 μg/ml.
CD133+ cells were isolated using magnetic bead separation
(Miltenyi Biotec, Auburn, CA). Frequency of CD133+ cells
was determined by flow cytometry using phycoerythrin-
(PE) conjugated monoclonal anti-CD133/2 antibodies
(Miltenyi Biotec, Auburn, CA).
Viability and cytotoxicity assays
MTT assay
Target cells (4x104 in a volume of 0.1 ml) were plated in
96-well flat bottom microtiter plates (Corning Inc.,
Corning, NY) and allowed to adhere. Effector cells were
added in a volume of 0.1 ml to achieve the effector:
target ratio (E:T) indicated and the plates incubated
overnight, allowing 16 hours for killing to occur. All
groups were performed in triplicate. Non-adherent ef-
fector cells were removed and viability of the remaining
target cells determined using MTT assay. Metabolism of
MTT to the formazan product is a measure of residual
viable cells, in contrast to 51Cr release, which is a direct
measure of cytotoxicity. We validated the use of the
former by confirming a linear relationship between viable
cell number and MTT signal and also by performing
MTT and 51Cr release in parallel and determining the cor-
relation coefficient of the two data sets.
51Cr Release assay
This was performed in 96-well flat-bottom microtiter
plates [6]. Target cells (4x104 cells/well) were plated and
allowed to adhere overnight, labeled with 51Cr at 37°C
for 4 hours, and then washed in situ to remove unincor-
porated isotope. Subsequently, effectors were added
to achieve a given E:T. 51Cr release was measured after 18
hours and percent cytotoxicity calculated as follows:
(experimental cpm – spontaneous cpm) / (maximum
cpm – spontaneous cpm) × 100. Triplicate determinations
were performed and the means and standard errors of the
triplicates calculated.
Bio-Plex assay for the measurement of cytokine secretion
Cytokines were quantitated in culture supernatants using
25-plex human cytokine Luminex Assay (Invitrogen,
Carlsbad, CA) in the Bio-Plex System (Bio-Rad Lab.,
Hercules, CA). The multiplex panel includes interleukin-
1β (IL-1β), IL-1 receptor antagonist (IL-1Ra), IL-2, IL-2R,
IL-4, IL-5, IL-6, IL-7, IL-8, IL-13, IL-17, tumor necrosis
factor (TNF)-α, interferon (IFN)-α, IFN-γ, granulocyte-
macrophage colony-stimulating factor (GM-CSF), macro-
phage inhibitory protein (MIP)-1α, MIP-1β, interferon-
inducible protein (IP)-10, monokine induced by IFN-γ
(MIG), eotaxin, regulated on activation normal T cell
expressed and secreted (RANTES), and monocyte chemo-
tactic protein (MCP)-1. The limit of detection for these
assays is <10 pg/mL based on detectable signal of >2 fold
above background. Cytokine concentration was calculated
by the Bio-Plex Manager Software using a standard curve
derived from recombinant cytokine standards.
Statistical analysis
Calculations of means and standard error of the mean
(±SEM), non-parametric correlation tests, and 1- and 2-
way ANOVA were performed using Prism5 (GraphPad
Software, San Diego, CA). All experiments were repeated
at least 3 times.
Results
Validation of MTT assay
Since our previous work with armed ATC employed the
51Cr release assay, we did parallel testing to confirm the
relationship between viable cell number and MTT assay
signal. We established in the glioma cell lines U251MG
(Figure 1) as well as glioma U118MG (data not shown)
and breast cancer line SKBR3 (data not shown), that ab-
sorbance (A570-A650) is a linear function (R
2 = 0.9930) of
the cell number up to 4 × 104 cells similar to counts per
minute (CPM) as a linear function (R2 = 1.0) of cytotox-
icity (Figure 1, lower panel). Hence, the MTT assay is a
reliable indicator of residual viable cells. Note that when
removal of unarmed ATC is incomplete, it may give rise
to values >100% in groups that received unarmed ATC
or control BiAb-ATC. When ATC were armed with
EGFRBiAb or HER2BiAb residual target viability clearly
was lower. In several experiments, parallel experiments
were performed in replicate 96-well plates tested using
MTT and specific cytotoxicity using 51Cr release. There
was a statistically-significant negative correlation (Spearman
r = −0.5804; exact two-tailed p value = 0.0479), validating
the MTTassay in this system.
Optimizing the arming dose of bispecific antibody
The lots of BiAbs were tested on unirradiated and
irradiated ATC from two normal donors by arming with
doses of 0, 5, 50, and 500 ng of HER2Bi or EGFRBi/106
ATC. A representative data using U118MG targets are
shown in Figure 2A, upper and lower panels. Similar
arming dose titration results were obtained with U87
and U251 targets (data not shown).
In the MTT assay, ATC armed with EGFRBi killed ef-
fectively at all 3 doses, essentially eliminating all U118
target cells, while ATC armed with HER2Bi showed
100% cytotoxicity at 5 ng and 50 ng arming dose,
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however, cytotoxic activity was reduced at 500 ng dose
(Figure 2A, upper panel). Similarly, the 51Cr release
assay showed higher cytotoxicity at 5 and 50 ng of
EGFRBi or HER2Bi/106 ATC with decreasing cytotox-
icity as the arming dose was increased to 500 ng of
HER2Bi or EGFRBi/106 ATC, which could be due to the
receptor saturation induced desensitization of ATC.
Similar results were observed with irradiated ATC or
aATC at 5, 50 and 500 ng arming doses (Figure 2A,
lower panel) and based on these results, we armed ATC
at 50 ng of HER2Bi or EGFRBi/106 ATC for subsequent
experiments. The data with the three donors in all three
cell lines (U87MG, U118MG and U251MG) using
unarmed ATC or armed ATC at 50 ng dose are shown
in Figure 2B. All experiments were repeated at least
three times.
Specific killing of long-term glioma cell lines by armed ATC
Flow cytometry analysis of U87MG, U118MG, and
U251MG confirmed that all 3 lines show high surface
expression of EGFR (80-100% cell positivity) while only
the latter two expressed low levels of surface HER2/neu
(U118MG: 17.6% and U251MG: 32.5% positive cells).
Figure 2C (lower panel) shows the histograms of EGFR
and HER2 expression (blue) compared to isotype control
(red), and plots for percent positive cells and mean
fluorescence intensity (MFI). The three lines were used
as targets for ATC armed with EGFRBi, HER2Bi, and
CD20Bi. Figure 2C (upper panel) shows residual viability
at E:T = 5:1. Unarmed ATC showed no reduction of
tumor cell viability; CD20Bi-armed ATC (irrelevant con-
trol) also showed no reduction of tumor cell viability for
U118 and U251 cells but showed reduced viability (80%)
Figure 1 Linearity of MTT and 51Cr responses of glioma lines. Upper panel: A representative data showing a linear correlation between OD
and cell numbers of U251MG glioma cell line. The indicated numbers of U251MG cells were incubated with MTT for 4 hours under standard
conditions. The assay was completed by the solubilization of formazan, the A570 and A650 nm measured, and the difference calculated. Lower
panel: Shows correlation between counts per minute (CPM) and % specific cytotoxicity using 51Cr release assay.
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for U87. CD20Bi-armed ATC mediated reduction in the
viability against U87 cells could be due to the nonspecific
binding of armed ATC to target cells resulting in effector
target interaction induced cytotoxicity. In contrast, all 3
tumor cell lines showed significant losses of viability when
exposed to EGFRBi-armed ATC. U118MG and U251MG
viabilities were reduced by HER2Bi-armed ATC (middle
and right columns), consistent with the surface expression
data, whereas HER2Bi-armed ATC (left column) failed to
reduce the viability of U87MG cells below 100%. The fetal
calf serum used to supplement medium was heat-
inactivated and preparation of BiAbs effectively eliminates
the complement-fixing properties of the Fc regions,
suggesting that aATC mediated cytotoxicity cannot be
accounted for complement dependent cytotoxicity.
Killing of fresh ex vivo glioma cells
Figure 3, upper panel shows susceptibility of one pri-
mary glioma cell line derived from resected tissue from
a patient with a histologically-confirmed glioblastoma.
FACS analysis showed both EGFR (9.99%) and HER2/neu
(7.15%) expression (Figure 3, bottom panel). The mean re-
sidual viabilities (and SEM) for 4 ATC donors are shown
when these cells were used as targets, over E:T ratios ran-
ging from 1.5:1 to 12.5:1. The data shown were pooled from
4 experiments. The curves for unarmed ATC and CD20Bi-
armed are essentially identical and show residual viabilities
fluctuating around 100%. In contrast, both HER2Bi- and
EGFRBi-armed ATC reduced viability to 15-20% over a
range of E:T from 1.5:1 to 12.5:1. This demonstrates that
glioma cells obtained from fresh tumors are appropriate
A C
B
MTT 51Cr Assay
Arming Dose
HER2
Isotype
EGFR
Isotype
U87 U118 U251
Figure 2 BiAb-armed ATC specifically kill long term glioma cell lines. 2A: Non-irradiated or irradiated ATC were armed with the indicated
amounts (ng/106 cells) of either EGFRBi (circles) or HER2Bi (triangles) and used as effector cells at an E:T of 5:1. The figure shows the results from
one of two donors, with U118MG cells as targets. Both MTT and 51Cr assays were used as readouts. 2B: Shows the data for U87MG, U118MG, and
U251MG cells using non-irradiated unarmed ATC or armed ATC at one arming dose of 50 ng for EGFRBi, HER2Bi and CD20Bi at E/T of 5:1. Both
MTT and 51Cr assays were used as readouts. 2C: U87MG, U118MG, and U251MG cells were exposed overnight to the indicated effector cells at an
E:T of 5:1 and residual viability determined by MTT assay. U87MG expresses only EGFR whereas U118MG and U251MG express both HER2/neu and
EGFR. Data were analyzed by 1-way ANOVA: for all 3 glioma lines, overall p < 0.0001; for all 3 lines, unarmed vs. CD20Bi p value is non-significant
(p > 0.05) (n.s.). 2C (lower panel): Shows the expression of EGFR and HER2 (blue) compared to isotype control (red), and plots for percent positive
cells and mean fluorescence intensity (MFI). For U87MG, Unarmed vs. HER2Bi, p > 0.05 (n.s.); Unarmed vs. EGFRBi, p < 0.001 (***). For U118MG,
Unarmed vs. HER2Bi and Unarmed vs. EGFRBi, p < 0.001 (***). For U251MG, Unarmed vs. HER2Bi and Unarmed vs. EGFRBi, p < 0.001 (***).
Zitron et al. BMC Cancer 2013, 13:83 Page 5 of 14
http://www.biomedcentral.com/1471-2407/13/83
targets and that ATC from different individuals show
general agreement in armed ATC function.
Does the simultaneous Use of Two BiAbs to Arm ATC
improve killing glioma targets?
Since there was a spectrum of expression levels of EGFR
and HER2/neu on the target cells, we investigated
whether simultaneous targeting using two BiAbs would
improve killing. Two approaches were tested: (i) com-
bining singly-armed populations of ATC effectors; and
(ii) arming ATC with EGFRBi and HER2Bi simultan-
eously. Primary glioma cells from two patients (08–32
and 08–33) were tested with armed ATC from 4 normal
donors at an E:T of 5:1 (Figure 4). Both malignant
***
*** *** ***
vs. Unarmed 
or CD20Bi
EGFR-FITC HER2/neu-FITC
9.99% 7.15%
Figure 3 Tumor cells in primary culture are specifically killed by BiAb-armed ATC. Ex vivo glioma cells expressing both HER2/neu and EGFR
were incubated overnight with unarmed ATC or ATC armed with HER2Bi, EGFRBi or CD20Bi. The data are pooled from 4 experiments, using 4
different ATC donors and a range of E:T. Residual viabilities (mean ± SEM) based upon MTT assays are shown. The targets are killed by HER2Bi-
and EGFRBi-armed ATC, whereas unarmed and CD20Bi-armed ATC fail to kill. Mean of 4 donors (± SEM), when compared with unarmed ATC, the
residual viable cells after HER2Bi- or EGFRBi-ATC were statistically significant (p < 0.001, 1-way ANOVA; ***). Arming with CD20BiAb showed no
statistically significant difference from unarmed ATC (p > 0.05, 1-way ANOVA; n.s.). Lower panel: Shows the HER2 (7.15%) and EGFR (9.99%)
expression as percent positive cells in this ex vivo cell line.
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glioma lines were histologically-confirmed specimens.
The unarmed and CD20Bi-armed ATC effectors did not
exhibit any cytotoxicity. Viabilities were >100% indicat-
ing that residual ATC increased the numbers of live
cells. The single BiAb-armed ATC showed efficient re-
duction with HER2Bi-armed ATC apparently being more
efficient than EGFRBi-armed cells. Data show evidence
for significantly enhanced loss of viable cells due
to mixing two effector populations, or to double-arming
a single population. One-way ANOVA indicated
no statistically significant difference between the
HER2Bi-armed ATC and the doubly-armed or mixed
single-armed. There was a significant difference when
comparing EGFRBi-armed cells with the double- or
mixed single-armed ATC, but this reflects the lesser effi-
ciency of the EGFRBi-armed ATC in this assay.
Additionally, there is no evidence that mixing or double-
arming compromises efficiency, when these two active
bispecific antibodies are used. These data show some
additive effect at least in one primary glioma cells (8–33)
with both BiAbs.
Are CD133 enriched cells, CD133− cells and unfractionated
tumor cells killed differentially by armed ATC?
We tested the susceptibility of unfractionated, CD133
enriched cells and CD133– cells from two ex vivo tumor
cell lines to killing by armed ATC from 3 normal
donors. ATC armed with HER2Bi or EGFRBi showed a
significant reduction in viability of all three target
populations at 5:1 E:T ratio (Figure 5, upper panel). At
the same E:T ratio (5:1), unarmed or CD20-armed ATC
showed insignificant effects on viability. Both putative
stem cells (CD133 enriched) and the bulk tumor popula-
tion are killed by armed ATC, at a low E:T (5:1) at which
the efficiency of the system is tested critically. Lower panel
of Figure 5 shows the expression of HER2 and EGFR in
CD133 enriched population from two primary cells.
Does chemoresistance confer protection against specific
cytotoxicity by armed ATC? Are armed ATC effective after
having undergone irradiation?
Since TMZ and radiation are generally given after sur-
gery for patients with glioblastoma, we determined
Figure 4 Targeting ATC to two molecules on the tumor cells’ surfaces enhances killing. Targets were ex vivo cells from two patients with
glioblastoma (08–32 and 08–33); both ex vivo lines expressed both HER2/neu and EGFR. The targets were exposed overnight (E:T = 5:1) to
unarmed ATC or ATC populations armed with single BiAb (ATC-HER2Bi, ATC-EGFRBi, ATC-CD20Bi), a mixture of equal numbers of singly-armed
HER2Bi- and EGFRBi-ATC (ATC-HER2Bi+ATC-EGFRBi) and a population of ATC simultaneously armed with HER2Bi and EGFRBi (ATC-HER2Bi,EGFRBi).
Mean residual viability was determined by MTT assay. For both 08-32 and 08-33 target cells, overall analysis by 1-way ANOVA, p < 0.0001.
Unarmed or CD20Bi-armed vs. HER2Bi-, EGFRBi and both doubly armed ATC, p < 0.0001 (***). HER2Bi vs. either doubly-armed ATC, p < 0.05 (only
for 8-33). EGFRBi vs. HER2Bi+EGFRBi, p < 0.01 (**). EGFRBi vs. HER2Bi,EGFRBi, p < 0.05 (*). Comparisons between individual effector cells performed
using Bonferroni multiple comparison test.
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whether armed ATC could kill glioma cells under com-
parable in vitro conditions. Our preliminary experiments
show that the TMZ-resistant U251MG could be killed
by armed ATC in the absence of TMZ (unpublished
data) and other studies showing radioresistance of armed
ATC effector function [14,15], we tested whether irradi-
ation and TMZ would inhibit cytotoxicity mediated by
unarmed and both HER2Bi- and EGFRBi-armed ATC.
These studies were done in parallel using MTT and 51Cr
release assays (Figure 6) and data were analyzed using
non-parametric statistics.
In the MTT assay, unarmed ATC did not kill glioma
targets. The 51Cr release cytotoxicity assay show <20%
cytotoxicity for unarmed ATC alone and ATC that
77%
30.7%
9% 7%
30.7%39%
Figure 5 Both CD133 enriched and CD133– glioma cells are susceptible targets for BiAb-armed ATC. Cells from an ex vivo glioblastoma
were separated into CD133– and CD133 enriched populations using magnetic separation (Miltenyi Biotec). The separated populations, stained
with a CD133/2-specific MAb are shown in the inset. Unfractionated (Unfx) cells and CD133– and CD133 enriched populations were incubated
overnight with unarmed ATC, or ATC armed with HER2Bi or CD20Bi, at an E:T of 3:1. The mean (± SEM) residual viability was determined using
the MTT assay. Lower panel: Show the expression of HER2 and EGFR in CD133 enriched population from two ex vivo primary cells. Overall analysis
by 1-way ANOVA, p < 0.0001. Individual comparison (Tukey-Kramer test): unarmed unfx vs. HER2Bi unfx p < 0.001 (***); unarmed unfx vs. CD20Bi
unfx p > 0.05 ; unarmed CD133– vs. HER2Bi CD133–p < 0.001 (***); unarmed CD133– vs. CD20Bi CD133–p < 0.001; unarmed CD133+ vs. HER2Bi
CD133+p < 0.05 (*); unarmed CD133+ vs. CD20Bi CD133+p < 0.01.
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Figure 6 Killing by armed ATC is resistant to both radiation and temozolomide. TMZ-resistant U251MG cells were used as target cells for
overnight killing by unarmed, HER2Bi-, and EGFRBi-armed ATC. The upper panel shows the MTT data and the lower panel shows 51Cr release
data. Each panel has three sets of 4 columns. The E:T was 10:1. The individual sets represent the effects of unarmed, HER2Bi-armed, and EGFRBi-armed
ATC, respectively. Within each data set, the 4 columns show the viability or cytotoxicity, respectively, for type of treatment with and without irradiation
or TMZ (final 100 μM). The four sets of effector cells were untreated (Radiation– TMZ–), irradiated only (Radiation+ TMZ–), exposed to TMZ only (100 μM
in the assay medium) (Radiation– TMZ+) and both irradiated and exposed to TMZ (Radiation+ TMZ+). Two assay plates were set up in parallel. The MTT
data are shown as mean (± SEM) residual percent viable cells and the mean (± SEM) 51Cr release data as percent cytotoxicity. Two-way ANOVA of the
MTT data show highly significant effects of both treatment and arming (p < 0.0001 for each), but no effect of interaction (p = 0.27). For the 51Cr data,
treatment (p < 0.0001), arming (p < 0.0001) and the interaction of the two (p = 0.0003) are all highly significant.
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receive radiation alone, TMZ alone, and the combination
of radiation and TMZ. Radiation alone had no effect on
the viability of either HER2Bi- and EGFRBi-armed ATC
(MTT data) but may have increased cytotoxicity (51Cr
release data) although was not statistically significant
(p=0.07). Exposure to TMZ alone showed a 25-28% re-
duction in MTT-viable cells with 38% reduction in 51Cr
specific cytotoxicity. These data suggest that TMZ may
be potentially toxic to ATC. Finally, combination of radi-
ation and TMZ shows 50-55% reduction in viable cells,
but only 9-15% reduction in cytotoxicity. Irradiation of
armed ATC results in 34-38% reduction in MTT-viable
cells when TMZ is present, but increased specific cyto-
toxicity of 38-46% (p=0.025). Therefore, the cytotoxic
capacity of armed ATC is not only radioresistant but can
kill in the presence of TMZ.
Do glioma cells exhibit suppressive or contact-dependent
inhibitory effects on ATC?
To test whether glioma cells or normal astrocytes se-
crete molecules that are capable of inhibiting the func-
tion of cytotoxic T cells, we incubated ATC for 6 days in
conditioned medium from both normal astrocytes and
two separate ex vivo glioma lines. We then tested
unarmed or armed ATC from these co-cultures for their
ability to kill U118MG and U251MG target cells. Expos-
ure of ATC or armed ATC to conditioned medium from
normal astrocytes or gliomas did not inhibit their cyto-
toxic activity towards U118MG or U251MG target cells
compared to the ability of control effectors that were
not treated with conditioned medium (data not shown).
Next, we asked whether cell-cell contact between armed
ATC and target cells inhibited cytotoxicity. For this, we
carried out a repeat killing assay, in a target cross-over
experiment (Figure 7). First, unarmed and HER2Bi-
armed ATC were incubated overnight, at E:T 10:1 with
either SK-BR-3 (irrelevant human breast cancer cells) or
U251MG cells. After removal of the non-adherent ATC,
the viability via MTT was <10% (>90% killing) for
HER2Bi on SK-BR-3 and U251MG targets (Culture 1 in
Figure 7). The recovered armed and unarmed ATC from
each co-culture were then re-plated onto cultures
containing the same or other tumor cell lines to deter-
mine whether they would kill again and whether they
would retain their specificity (Culture 2 in Figure 7).
Specifically-armed ATC from SK-BR-3 co-culture
showed reduced killing of U251MG cells and slight re-
duction in second killing of SK-BR-3 cells but ATC from
U251 co-culture showed no reduction in killing for ei-
ther cell lines. These data confirm that armed ATC can
mediate their effects more than once; furthermore, co-
cultures with gliomas cells did not suppress the ability of
armed ATC to kill glioma cells.
Are cytokines secreted by armed ATC?
Using ATC from two donors, we incubated unarmed
and EGFRBi armed ATC both alone and with U251 cells
(E:T = 25:1) and recovered the culture supernatants after
overnight incubation. Cytokine levels in the culture
supernatants were determined using the Bio-Plex assay.
The data for cytokines that showed significant changes
are shown in Figure 8 and reflect the means of the two
donors. Similar cytokine profile was obtained with U87
and U118 cell lines (data not shown).
Three Th1 cytokines (IFN-γ, GM-CSF, and TNF-α) and
one Th2 cytokine (IL-13) showed increases in concen-
tration when the armed ATC were incubated with
targets cells. The unarmed ATC secreted 500—840 pg
IFN-γ/106cells/24 hrs when incubated alone or with target
cells, however armed ATC incubated alone secreted little
or no IFN-γ, whereas incubation EGFRBi armed ATC with
U251 cells elicited induced 1400—2600 pg/ml of IFN-γ
secretion. The other cytokines in Figure 8 show very low
baseline concentrations that are clearly increased when
they are co-incubated with target cells.
Discussion
High-grade gliomas are aggressive tumors and respond
poorly to all treatment modalities. Since these tumors
are highly infiltrative, surgical resection leaves a
residuum of cells responsible for recurrence. Malignant
gliomas are almost uniformly lethal, with a median sur-
vival of about 15 months. This underscores the need for
effective, non-toxic strategies that can eliminate the
residual tumor cells and also, perhaps, immunize the
endogenous immune system against the tumor.
Our immunotherapy approach originates from a series
of studies, in which T cells have been redirected to EpCam
on adenocarcinomas [3]; HER2/neu on prostate [7], breast
[6], and ovarian cancer [5]; EGFR on a variety of tumor
types [4]; and CD20 on malignant B cells [7]. These stud-
ies were performed in vitro, in small animal models, and
have progressed to clinical trials [16]. In a recent study, we
have shown the involvement of Granzyme B (GrzB) and
IFN-γ signaling pathways in BiAb armed ATC mediated
cytotoxicity of target cells [17].
This study shows that both long-term glioma lines and
primary cultures of freshly-resected glioblastoma are ef-
ficiently killed by ATC armed with either HER2Bi or
EGFRBi, indicating that both antigens are potential
targets. We also showed that killing is not enhanced by
using both BiAbs simultaneously. It may be that, in fu-
ture studies, individual gliomas will show differential ex-
pression of HER2/neu and EGFR and that it will be
prudent to both phenotype and functionally test each
tumor as a target, in order to choose the best BiAb.
Cells with the stem-like property of self-renewal and
the ability to differentiate into the bulk population of
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tumor cells have been identified in a number of different
solid tumor types, amongst the best characterized of
which are breast [18] and gliomas [19]. CD133 was the
initial marker identified as characterizing the glioma
cancer stem cell, although there are subsequent reports
of CD133– cells with similar behavior [20]. The import-
ant additional features of stem cells are that they have
been postulated to be both chemo- and radioresistant
and to be responsible for the extensive infiltration seen
in gliomas [21]. The ability to kill CD133+ and CD133−
cells, as shown above, indicates that these stem-like cells
may be susceptible to killing in this system.
We showed that TMZ-resistant U251MG cells are also
susceptible to targeted killing and that armed ATC still
kill in the presence of TMZ. TMZ-resistant U251MG
cells were <1% CD133+. This may be due to the length
Figure 7 Armed ATC show sequential killing and effector function is unaffected by contact with glioma cells. In the first overnight
culture (Culture 1) unarmed ATC or HER2Bi-armed ATC were incubated with SKBR3 or U251MG target cells (first kill) (E:T = 10:1). The effector cells
were removed and MTT added to the wells to determine residual viability compared to control target cells to which no effectors had been
added. Data are means (± SEM) of 9–11 cultures. After overnight incubation, without any additional IL-2, the unarmed or HER2Bi-armed ATC were
used in a second culture (Culture 2), in which they were added to fresh targets or irrelevant targets (E:T = 10:1). After overnight incubation
(second kill), the effectors were removed and MTT added to the wells to determine residual viability of the targets. Data are shown as mean
(± SEM) of 4–7 cultures in each group.
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of time this line has been in culture, but their suscepti-
bility does indicate that glioma cells that do not have
stem-like properties but acquire chemoresistance are
also suitable targets for BiAb-armed ATC. We also
demonstrated the radioresistance of armed ATC effector
function and an indication that irradiation of ATC may
cause an increase in cytotoxicity. One possible interpret-
ation is that there is a radiosensitive population of cells
in the ATC that suppresses cytotoxic activity. Whether
this involves active suppression or merely reflects death of
the radiosensitive cells remains unclear. These results sug-
gest that patients undergoing conventional chemoradiation
may be suitable candidates for treatment with armed ATCs.
Some tumor types have been shown to produce sol-
uble factors that inhibit immune effectors [22] and
others to express membrane molecules, such as FasL
that actually kill effectors [23-29]. We ruled-out the
former by showing that long-term incubation of ATC in
culture supernatants from immortalized malignant gli-
oma lines and ex vivo gliomas and non-neoplastic
astrocytes do not inhibit killing activity. We tested the
latter, using long-term tumor lines and showed that
these, at least, do not diminish the cytotoxic activity of
armed ATC. That is, co-culture of armed ATC with gli-
oma cells permits repeat killing [10].
Finally, we also showed that when armed ATC are
incubated with targets, there is increased secretion of
three Th1 cytokines (IFN-γ, GM-CSF, and TNF-
.alpha;) and one Th2 cytokine (IL-13). The armed ATC are
the presumed source of the Th1 cytokines and their secre-
tion would serve to activate microglia (IFN-γ), act as an
adjuvant for immunization of endogenous lymphocytes
(GM-CSF) and potentially augment the killing of target
tumor cells (TNF-α). The cellular origin of the IL-13 is
probably also the ATC, since CD8+ T cells have been
shown to secrete this cytokine [30]. However, an IL-13 re-
ceptor is expressed on some glioma cells [31] and IL-13
has been shown to be an autocrine growth factor for both
Reed-Sternberg cells in Hodgkin’s disease [32-35] and pan-
creatic cancer [36]. The potential contribution of the gli-
oma cells to the increased IL-13 is under investigation.
Several studies have shown promising results in glio-
blastoma using various immunotherapeutic approaches
[37]. Lymphokine-activated killer (LAK) cells generated
from PBMC by co-culture with IL-2 have been reported
to selectively kill glioma cells in vitro and when placed
into the resection cavity with minimal systemic or
neurological side effects [38,39]. In the first study in
which cells were targeted to WHO grade III/IV gliomas,
LAK cells were treated with a conjugate of anti-CD3
cross-linked to the NE-150 monoclonal antibody which
recognizes an epitope of NCAM [40]. In the control
group which received untreated LAK cells, 9/10 patients
experienced recurrence within 1 year and 8/10 died
within 4 years. In the experimental group, 2/10 showed
no response, 4/10 showed regression and 4/10
had complete response. No recurrences occurred during
10—18 months of follow-up in the 8 patients showing
partial or complete response. Subsequently, others have
reported the use of different BiAbs both in vitro and
early-stage clinical trials [41-46].
Conclusions
In conclusion, high-grade gliomas appear to be suitable
targets for specific targeting by armed ATC. Should
these results be confirmed in animal studies, comparable
to those performed with other tumor targets, this ap-
proach may represent an additional adjuvant treatment
for this devastating malignancy.
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